Pathnostics

Established in 2011, Pathnostics is driven to pioneer a better future for physicians, patients, and the healthcare system with solutions that transform diagnostic and therapeutic dilemmas. Core capabilities in infectious disease and cancer diagnostics. A CAP-accredited and CLIA-certified laboratory, Pathnostics drives forward patient care with its range of unique and advanced tests with a robust offering of histopathology, cytology, and molecular tests, including: Pathnostics believes in robust science to demonstrate safety, efficacy, and clinical utility. To date, we have completed three (3) clinical studies involving more than 68,000 subjects for Guidance UTI, our flagship platform that combines molecular detection with our proprietary Pooled Antibiotic Susceptibility Testing (P-AST™) technology. Key findings are published in six (6) peer-reviewed journals.